SCHEMBL10116356

SCHEMBL10116356

COc1ccc(NC(=O)c2ccc(NS(=O)(=O)C(C)(C)C)cc2)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.53
LMNA P02545 4/20 0.51
NPC1 O15118 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
RAB9A P51151 3/20 0.51
AHR P35869 1/20 0.51
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
MAPT P10636 5/20 0.50
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
CCR8 P51685 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
TP53 P04637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116412 0.84 MAPT (0.47) LMNANPC1SMN1; SMN2RAB9AMAPT
SCHEMBL10114515 0.84 RAB9A (0.69) LMNANPC1SMN1; SMN2RAB9AMAPT
SCHEMBL10116355 0.83 ALDH1A1 (0.69) LMNANPC1SMN1; SMN2RAB9AMAPT
SCHEMBL10116297 0.83 ALDH1A1 (0.57) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL10116407 0.83 MAPT (0.48) LMNANPC1SMN1; SMN2RAB9AMAPT
SCHEMBL10116414 0.83 MAPT (0.49) LMNANPC1MAPTALDH1A1MEN1
SCHEMBL10116317 0.79 MAPT (0.48) LMNARAB9AMAPTALDH1A1MEN1
SCHEMBL13565044 0.78 MAPT (0.47) LMNANPC1SMN1; SMN2RAB9ACA12
SCHEMBL10116436 0.77 HDAC1 (0.46) LMNANPC1RAB9AMAPTALDH1A1
SCHEMBL11826733 0.77 RAB9A (0.65) F10LMNANPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R F10 2622/4885LMNA 1925/4885NPC1 1435/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R F10 2892/4885LMNA 2068/4885NPC1 1353/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R F10 2545/4885LMNA 1857/4885NPC1 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.